Pharmaceutical Business review

Biogen Idec Q4 revenue rises

For the fourth quarter of 2010, the company has generated net income of $271.75m, compared to $306m for the same period in 2009.
However, the income from operations was $355.19m, compared to $383.38m for the same period in 2009.

For the full year ended 31 December 2010, the company posted total revenues of $4.72bn, compared to $4.38bn for the same period in 2009.

Biogen Idec‘s net income was $898.57m for the full year of 2010, compared to $977.06m for the same period in 2009.
Income from operations was $1.25bn, compared to $1.3bn for the same period in 2009.

Biogen Idec CEO George Scangos said their solid 2010 performance reflects the strength of their core business.

"We will continue the company’s transformation in 2011, and we’re looking forward to several key pipeline milestones in the coming months," Scangos said.